{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:04:23Z","timestamp":1790283863075,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s12325-022-02217-y","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T12:03:52Z","timestamp":1657195432000},"page":"4131-4145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Reduced Healthcare Resource Utilization in Patients with Opioid Use Disorder in the 12\u00a0Months After Initiation of a Prescription Digital Therapeutic"],"prefix":"10.1007","volume":"39","author":[{"given":"Fulton F.","family":"Velez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn P.","family":"Anastassopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Colman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Kauffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Ruetsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri A.","family":"Maricich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"2217_CR1","unstructured":"Centers for Disease Control & Prevention. Understanding the epidemic 2019. https:\/\/www.cdc.gov\/drugoverdose\/epidemic\/index.html. Accessed 29 Mar 2022."},{"issue":"4","key":"2217_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","volume":"34","author":"D Ciccarone","year":"2021","unstructured":"Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344\u201350.","journal-title":"Curr Opin Psychiatry"},{"key":"2217_CR3","unstructured":"Centers for Disease Control & Prevention. Increse in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic. https:\/\/emergency.cdc.gov\/han\/2020\/han00438.asp?ACSTrackingID=USCDC_511-DM44961&ACSTrackingLabel=HAN%20438%20-%20General%20Public&deliveryName=USCDC_511-DM44961. Accessed 29 Mar 2022."},{"key":"2217_CR4","unstructured":"Centers for Disease Control & Prevention. Vital statistics rapid release: provisional drug overdose death counts. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm. Accessed 29 Mar 2022."},{"key":"2217_CR5","unstructured":"Centers for Disease Control & Prevention. Nonfatal drug overdoses. https:\/\/www.cdc.gov\/drugoverdose\/nonfatal\/index.html. Accessed 29 Mar 2022."},{"key":"2217_CR6","unstructured":"Assistant Secretary for Planning and Evaluation, US Department of Health and Human Services. Non-fatal opioid overdose and associated health outcomes: final summary report September 2019. https:\/\/aspe.hhs.gov\/reports\/non-fatal-opioid-overdose-associated-health-outcomes-final-summary-report-0. Accessed 29 Mar 2022."},{"issue":"6","key":"2217_CR7","first-page":"e172","volume":"23","author":"C Ruetsch","year":"2017","unstructured":"Ruetsch C, Tkacz J, Nadipelli VR, et al. Heterogeneity of nonadherent buprenorphine patients: subgroup characteristics and outcomes. Am J Manag Care. 2017;23(6):e172\u20139.","journal-title":"Am J Manag Care"},{"issue":"1","key":"2217_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1940-0640-9-16","volume":"9","author":"FL Lynch","year":"2014","unstructured":"Lynch FL, McCarty D, Mertens J, et al. Costs of care for persons with opioid dependence in commercial integrated health systems. Addict Sci Clin Pract. 2014;9(1):16.","journal-title":"Addict Sci Clin Pract"},{"key":"2217_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/SAR.S150253","volume":"9","author":"NA Ronquest","year":"2018","unstructured":"Ronquest NA, Willson TM, Montejano LB, Nadipelli VR, Wollschlaeger BA. Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder. Subst Abuse Rehabil. 2018;9:59\u201378.","journal-title":"Subst Abuse Rehabil"},{"key":"2217_CR10","unstructured":"American Society of Addiction Medicine. National practice guideline for the treatment of opioid use disorder, 2020 Focused Update."},{"key":"2217_CR11","unstructured":"Substance Abuse and Mental Health Services Administration. TIP 63: medications for opioid use disorder (updated 2021). https:\/\/store.samhsa.gov\/sites\/default\/files\/SAMHSA_Digital_Download\/PEP21-02-01-002.pdf. Accessed 29 Mar 2022."},{"issue":"6","key":"2217_CR12","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1037\/a0037496","volume":"82","author":"DR Christensen","year":"2014","unstructured":"Christensen DR, Landes RD, Jackson L, et al. Adding an internet-delivered treatment to an efficacious treatment package for opioid dependence. J Consult Clin Psychol. 2014;82(6):964\u201372.","journal-title":"J Consult Clin Psychol"},{"issue":"1","key":"2217_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/14737167.2021.1840357","volume":"21","author":"FF Velez","year":"2021","unstructured":"Velez FF, Colman S, Kauffman L, Ruetsch C, Anastassopoulos K. Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1):69\u201376.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2217_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jsat.2016.08.016","volume":"71","author":"BA Moore","year":"2016","unstructured":"Moore BA, Fiellin DA, Cutter CJ, et al. Cognitive behavioral therapy improves treatment outcomes for prescription opioid users in primary care buprenorphine treatment. J Subst Abuse Treat. 2016;71:54\u20137.","journal-title":"J Subst Abuse Treat"},{"key":"2217_CR15","unstructured":"National Institute on Drug Abuse. Principles of drug addiction treatment: a research-based guide (third edition): drug addiction treatment in the United States. https:\/\/www.drugabuse.gov\/publications\/principles-drug-addiction-treatment-research-based-guide-third-edition\/drug-addiction-treatment-in-united-states. Accessed 29 Mar 2022."},{"key":"2217_CR16","unstructured":"Pear Therapeutics Inc. reSET-O [clinician directions for use]. 2017."},{"issue":"6","key":"2217_CR17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1176\/appi.ajp.2014.13081055","volume":"171","author":"AN Campbell","year":"2014","unstructured":"Campbell AN, Nunes EV, Matthews AG, et al. Internet-delivered treatment for substance abuse: a multisite randomized controlled trial. Am J Psychiatry. 2014;171(6):683\u201390.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"2217_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/03007995.2020.1846022","volume":"37","author":"YA Maricich","year":"2021","unstructured":"Maricich YA, Bickel WK, Marsch LA, Gatchalian K, Botbyl J, Luderer HF. Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder. Curr Med Res Opin. 2021;37(2):167\u201373.","journal-title":"Curr Med Res Opin"},{"key":"2217_CR19","first-page":"1","volume":"2","author":"YA Maricich","year":"2021","unstructured":"Maricich YA, Gerwien R, Kuo A, Malone DC, Velez FF. Real-world use and clinical outcomes after 24 weeks of treatment with a prescription digital therapeutic for opioid use disorder. Hosp Pract. 2021;2:1\u20138.","journal-title":"Hosp Pract"},{"key":"2217_CR20","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2147\/CEOR.S334274","volume":"13","author":"F Velez","year":"2021","unstructured":"Velez F, Colman S, Kauffman L, et al. Comparison of healthcare resource utilization between patients who engaged or did not engage with a prescription digital therapeutic for opioid use disorder. ClinicoEconomics Outcomes Res. 2021;13:909\u201316.","journal-title":"ClinicoEconomics Outcomes Res"},{"issue":"1","key":"2217_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44\u20137.","journal-title":"Value Health"},{"key":"2217_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108306","volume":"218","author":"A Arifkhanova","year":"2021","unstructured":"Arifkhanova A, McCormick Kraus E, et al. Estimating costs of hospitalizations associated with opioid use disorder or opioid misuse at a large, urban safety-net hospital-Denver, Colorado, 2017. Drug Alcohol Depend. 2021;218: 108306.","journal-title":"Drug Alcohol Depend"},{"key":"2217_CR23","unstructured":"Centers for Medicare and Medicaid Services (CMS). Medicare Hospital Outpatient Prospective Payment System Addendum A, April 2020 file. 2020. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-For-Service-Payment\/HospitalOutpatientPPS\/Addendum-A-and-Addendum-B-Updates. Accessed 29 Mar 2022."},{"issue":"3","key":"2217_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.0242","volume":"4","author":"C Peterson","year":"2021","unstructured":"Peterson C, Li M, Xu L, Mikosz CA, Luo F. Assessment of annual cost of substance use disorder in US hospitals. JAMA Netw Open. 2021;4(3): e210242.","journal-title":"JAMA Netw Open"},{"key":"2217_CR25","first-page":"1","volume":"2021","author":"FF Velez","year":"1995","unstructured":"Velez FF, Colman S, Kauffman L, Anastassopoulos K, Murphy S, Maricich Y. Real-world changes in US health system hospital-based services following treatment with a prescription digital therapeutic for opioid use disorder. Hosp Pract. 1995;2021:1\u20137.","journal-title":"Hosp Pract"},{"issue":"4","key":"2217_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/14737167.2021.1939687","volume":"21","author":"FF Velez","year":"2021","unstructured":"Velez FF, Ruetsch C, Maricich Y. Evidence of long-term real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):519\u201320.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02217-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02217-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02217-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T03:13:03Z","timestamp":1665803583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02217-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["2217"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02217-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"assertion":[{"value":"22 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}